Neuromuscular blocking drugs Flashcards Preview

PHAR2002 > Neuromuscular blocking drugs > Flashcards

Flashcards in Neuromuscular blocking drugs Deck (21):
1

Why are these drugs used?

To cause muscle paralysis with intubation (esp. suxamethonium b/c fast onset + short duration) + abdominal surgery (less anaesthetia used) and to assis ventilation in intensive care

2

Competitive blockers are also known as _____ and examples are ___

non-depolarising curares, e.g. tubocurarine, vecuronium, pancuronium + atracurium

3

Competitive blocker characteristics

High affinity for nAChR's -> long residence in binding site so ACh release can't effect synaptic potential -> too small to elicit a.p.

4

Features of competitive block:

1. Relaxation without preliminary excitation of muscles
2. Relaxant effect antagonised by anticholinesterases
3. Tetanic "fade" more pronounced
4. Myastenia gravis patients (autoimmune loss of ACh receptors) normally sensitive

5

Why may a cholinesterase blocker be used against a competitive blocker?

Reverse the administration of a competitive blocker as the duration of these blockers is quite long

6

Only example of a depolarising blocker

Suxamethonium = agonist of nAChr

7

How is suxamethonium different to ACh

Resistant to hydrolysis by local cholinesterase so can bind and rebind to receptor -> sustained depol of endplate muscle fibre

8

Why does mucle fibre membrane become inexcitable after initial a.p. with suxamethonium

Na channels around endplate inactive can't generate ap

9

Features of depolarisation block:

1. Initial fasciculation -> endplate depol. causes excitation of muscle fibres -: post-op muscle pain
2. Block not relieved by anticholinesterases
3. Myasthenia gravis patients insensitive to blocking action
4. Action at endplate causes release of K+ from muscle cells -> hypokalaemia

10

Why can K+ release from suxamethonium be dangerous?

If plasma K+ already high (in severe burns or crush injuries) or if K+ release enhanced (disease/ injuries causing denervation)

11

Suxamethoniums relationship with cholinesterase

CHE from PLASMA. so action lasts only 5 mins
- If plasma CHE level low, action can be prolonged to several hours

12

Causes of low plasma CHE

Genetic abnormality due to mutation or liver disease, malnutrition or use of anticholinesterase drugs

13

What terrible side effect can be seen if suxamethnoium is used with GA's in a susceptible patient and why are they susceptible

Malignant hyperthermia, someone with a mutation in calcium release channel on SR since calcium release produces persistent muscle spasm and hyperthermia

14

3 compounds that block cholinergic transmission

1. Botulinum toxin
2. hemincholinium
3. streptomycin

15

Botulinum toxin origins

High molecular weight protein produced by an anaerobic bacillus (clostridium botulinum) which can grow in badly tined food -> rare but highly dangerous cause of food poisoning

16

Potency of botulinum toxin

Letal dose 70. ig and its effects are long lasting (weeks)

17

Botulinum toxin mech of action and uses

Blocks release of ACh at NMJ and ganglia without affecting postsynaptic mech's -: prolonged relief of muscle spas min dystonia in severe localised excessive sudoration

18

Hemicholinium characteristics

- Structurally similar to choline

19

Hemicholinium mech of action and uses

- competitively inhibits uptake of choline by cholinergic nerve terminals
-> active, carrier-mediated transport
-> causes terminals to run short of choline, so ACh synthesis can't keep up with release
- Action - slow -> mainly experimental

20

Streptomycin is a ____ antibiotic

aminoglycoside

21

Streptomycin means of action and side effect

Inhibit ACh by blocking Ca entry -> weakness as a side effect + potentiates action of neuromuscular blocking agents in anaesthetia